Loading…
Loading…
IQV does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for IQV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IQV and 80,000+ other tickers.
See exactly how IQV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IQV and 80,000+ other tickers.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions…
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Andra AP fonden raised its stake in IQVIA Holdings Inc. (NYSE: IQV) by 320.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 121,405 shares of the medical research company's stock after purchasing an additional 92,505 shares during the quarter. Andra AP fonden
Cantillon Capital Management LLC lowered its position in IQVIA Holdings Inc. (NYSE: IQV) by 11.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,710,896 shares of the medical research company's stock after selling 230,248 shares during the
California Public Employees Retirement System increased its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 2.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 337,191 shares of the medical research company's stock after buying an additional 6,563 shares during the period. California Public Employees
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.